We are live on ! Find out more
CPRX icon

Catalyst Pharmaceutical
CPRX

135 hedge funds and large institutions have $222M invested in Catalyst Pharmaceutical in 2020 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 40 increasing their positions, 50 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

10% more capital invested

Capital invested by funds: $202M → $222M (+$20.3M)

1.4% less ownership

Funds ownership: 65.63% → 64.23% (-1.4%)

5% less funds holding

Funds holding: 142 → 135 (-7)

20% less repeat investments, than reductions

Existing positions increased: 40 | Existing positions reduced: 50

22% less first-time investments, than exits

New positions opened: 18 | Existing positions closed: 23

26% less call options, than puts

Call options by funds: $233K | Put options by funds: $313K

Holders
135
Holders Change
-7
Holders Change %
-4.93%
% of All Funds
2.39%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
18
Increased
40
Reduced
50
Closed
23
Calls
$233K
Puts
$313K
Net Calls
-$80K
Net Calls Change
-$610K

Top Buyers

1
Vanguard Group
Vanguard Group
Pennsylvania
+$2.76M
2
Goldman Sachs
Goldman Sachs
New York
+$2.32M
3
RA
Royce & Associates
New York
+$2.08M
4
N
Nuveen
North Carolina
+$1.79M
5
Millennium Management
Millennium Management
New York
+$1.37M

Top Sellers

1
MP
Mangrove Partners
Connecticut
-$9.01M
2
Morgan Stanley
Morgan Stanley
New York
-$8.78M
3
State Street
State Street
Massachusetts
-$5.1M
4
BBA
Baker Bros. Advisors
New York
-$1.41M
5
EGM
Engineers Gate Manager
New York
-$699K
Name Holding Trade Value Shares
Change 		Change in
Stake
GCM
26
Gables Capital Management
Florida
$1.38M -$65.5K -19,500 -5%
GC
27
Globeflex Capital
California
$1.26M +$1.26M +376,207 New
Two Sigma Investments
28
Two Sigma Investments
New York
$1.23M +$1.24M +369,071 New
Los Angeles Capital Management
29
Los Angeles Capital Management
California
$1.21M -$88.4K -26,320 -7%
BGIM
30
Brandywine Global Investment Management
Pennsylvania
$1.19M -$310K -92,355 -21%
D.E. Shaw & Co
31
D.E. Shaw & Co
New York
$1.19M -$332K -98,857 -22%
Bank of Montreal
32
Bank of Montreal
Ontario, Canada
$1.17M +$207K +61,504 +22%
WVP
33
Worth Venture Partners
New Jersey
$1.15M +$255K +76,020 +28%
WANY
34
Wealthspire Advisors (New York)
New York
$1.13M – – –
Jacobs Levy Equity Management
35
Jacobs Levy Equity Management
New Jersey
$1.13M +$380K +113,140 +50%
UBS Group
36
UBS Group
Switzerland
$1.1M +$181K +53,741 +19%
Arrowstreet Capital
37
Arrowstreet Capital
Massachusetts
$986K +$992K +295,292 New
AA
38
ALPS Advisors
Colorado
$885K +$177K +52,699 +25%
Barclays
39
Barclays
United Kingdom
$849K -$41.7K -12,411 -5%
Bank of America
40
Bank of America
North Carolina
$806K -$106K -31,542 -12%
HW
41
Hancock Whitney
Mississippi
$799K -$181K -53,928 -18%
RJFSA
42
Raymond James Financial Services Advisors
Florida
$791K -$84 -25 -0%
Wells Fargo
43
Wells Fargo
California
$790K -$226K -67,272 -22%
First Trust Advisors
44
First Trust Advisors
Illinois
$779K -$34K -10,106 -4%
TCM
45
Tanaka Capital Management
New York
$752K -$90.5K -26,925 -11%
California Public Employees Retirement System
46
California Public Employees Retirement System
California
$752K -$14.1K -4,200 -2%
Swiss National Bank
47
Swiss National Bank
Switzerland
$732K – – –
PC
48
Prairiewood Capital
North Dakota
$713K +$717K +213,432 New
UBS AM
49
UBS AM
Illinois
$651K +$328K +97,700 +100%
CS
50
Credit Suisse
Switzerland
$646K -$378K -112,569 -37%
1
2
3 4 5

CPRX Hedge Fund Activity: Q4 2020 in Review

135 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Catalyst Pharmaceutical (CPRX) for Q4 2020, worth a combined $222M — up 10% from $202M a quarter earlier.

Sellers outnumbered buyers: 23 funds closed out of CPRX and 18 opened new positions — a net loss of 5 holders — while 50 trimmed existing stakes and 40 added.

The largest buyer was Vanguard Group, adding an estimated $2.76M. The largest seller was Mangrove Partners, exiting entirely with an estimated $9.01M sold.

  • 135 institutional investors held Catalyst Pharmaceutical (CPRX) as of Q4 2020, down from 142 in Q3 2020.
  • Funds reported $222M of Catalyst Pharmaceutical stock for Q4 2020, up 10% quarter-over-quarter.
  • 18 funds opened new Catalyst Pharmaceutical positions in Q4 2020 and 23 closed out, a net change of -5 holders.
  • The largest Catalyst Pharmaceutical buyer in Q4 2020 was Vanguard Group, an estimated $2.76M added.
  • The largest Catalyst Pharmaceutical seller in Q4 2020 was Mangrove Partners, an estimated $9.01M sold.

Based on aggregated 13F filings for Q4 2020.